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Abstract 
Based on complementary ethnographies of a biomedical laboratory and a clinic – both working 
on Huntington Disease (HD) – we discuss the circuits of translation evident in biomedical and 
clinical research. By examining a recent epistemological shift from understanding the disease 
as genetic to understanding the disease as a problem for neuroscience, as well as documenting 
the multiple framings of the disease that migrate between the laboratory and the clinic, we 
emphasise the complexity involved in the movement of biomedical science into clinical work. 
We stress that this is not a one-way flow from the colloquially known bench to bedside, but is 
dependent on a cluster of contextual activities and local actors. We also stress the extent to 
which global collaborations, standardisation and regulatory frameworks can facilitate such 
framing and migration by aligning local practices and different disciplinary outlooks. We take 
a sociological perspective on translational processes – or rather to an expanded understanding 
of translation – to capture the material flows and conceptual transformations that are involved 
in the complex relationships between fundamental and clinical research. 
Keywords: Translation, Huntington’s Disease (HD), Ethnography, Relocation, Realignment, 
Standardisation 
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Relocation, Realignment, and Standardisation: Circuits of Translation in Huntington’s 
Disease 
Introduction 
Biomedical research is increasingly described and justified in terms of the metaphor of 
‘translation’ (Martin, Brown and Kraft, 2008). This is often portrayed as the passage of 
laboratory-based research into clinical treatments. The linear model of basic research  
applied research  clinical intervention or technological product was developed during the 
twentieth century as a rhetorical tool used by scientists (Godin, 2006). To quote Vannevar 
Bush (1945) “basic research leads to new knowledge…It creates the fund from which the 
practical application of knowledge must be drawn. New products and new processes…are 
founded on new principles and new conceptions, which in turn are painstakingly developed 
by research in the purest realms of science” (p19). Here we take a sociological perspective on 
translational processes – or rather to an expanded understanding of translation. We suggest 
that there are complex processes of migration and circulation that extend the notion of 
translation. We maintain that translation is not simply the uni-directional movement from 
bench to bedside (Bush, 1945), nor the bi-directional movement of bench to bedside and 
bedside to bench (Keating, 2002; Löwy, 1996; Sartor, 2003).  Equally, it is not solely a 
rhetorical device used to promote enthusiasm for the research (Wainwright et al., 2006); 
although precisely because it is rhetorically powerful in justifying research, it is important to 
take a broader perspective. We argue that ‘translation’ is multi-directional and multi-modal: 
objects, knowledge, practices and resources are circulated between multiple sites. ‘Matter’ 
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and ‘matters’ migrate – physically or virtually - from one site to another. In the process they 
cross a variety of boundaries and potential barriers.  
In particular, we describe the relative success achieved by one research group in 
mobilising the promise of cellular applications for Huntington Disease (HD) to develop 
research collaborations.   In our example, there is a process of alignment between the 
knowledge-systems of the laboratory and the knowledge-systems of the clinic as scientists 
and clinicians render HD doable through the careful coordination, cooperation and calibration 
of the laboratory with the clinical and social worlds. In the process, instruments, biomedical 
tests and patients are configured as well (Keating and Cambrosio, 2003). These future-based 
networks are communities of promise, and in this particular case of the HD research clinic 
they traverse between the local and the global facing at least some of the impediments 
discussed by Martin, Brown, and Kraft (2008), including different working practices and 
diverse disciplinary outlooks.  
We draw on two separate ethnographic studies conducted at sites situated within the 
translational operation - the laboratory (known here as Headlab) and the clinic (known here 
as Neurotest). We argue that an ethnographically-based, sociologically informed analysis of 
these processes permits a more sophisticated grasp of the circuits of collaboration and 
implementation than does a simple one-way, or even two-way, approach to ‘translation’. 
Most importantly, we argue, ‘translation’ implies the multiple framings of disease entities, 
that in turn imply more complex epistemological work than might be understood in terms of 
the unproblematic ‘transfer’ of stable knowledge or practices from one site to another 
(Wainwright et al., 2006; Wainwright et al., 2009). The complex and messy reality of 
biomedical science rests on the practical integration of many different social worlds. 
Furthermore, scientific and medical phenomena are themselves translated and transformed in 
the process. 
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Our research suggests that the concept of ‘translation’ often fails to capture the 
material flows and conceptual transformations that are involved in the complex relationships 
between fundamental and clinical research. In the case of HD, we identify three major forms 
of transformation. First, in order for HD to be rendered observable and measurable in the 
clinic, it has been relocated: it has been re-framed as a neurological condition, rather than as 
a genetic one. Consequently, clinical observations and measurements of behaviour and 
cognitive function can be conducted in the interests of clinical research. Such relocation 
implies a change in professional personnel, a shift in technologies of assessment, and a 
physical relocation from one clinical site to another within the hospital. Secondly, there has 
been a process of realignment in order to render congruent the laboratory model of HD and 
the manifestations of HD in the neurological clinic. Technologies of visibility (Lynch, 1990; 
Galison, 1997; Dumit, 2004) and processes of measurability (Keating and Cambrosio, 2003) 
aid such arrangement. Laboratory science is translated into a clinically applicable practice 
and clinical phenomena are translated into researchable laboratory topics. Thirdly, there is an 
imperative to standardise HD in the laboratory and clinic in the interests of globally 
distributed research collaboration. Translational research is dependent on the collaboration 
between scientists and clinicians, and standardisation enables multiple parties to work 
together across boundaries (Fujimura, 1992). Relocation, realignment and standardisation are 
thus among the cognitive and institutional strategies implicated in the circuits of translation.  
Research Context 
Ethnographic fieldwork was conducted in the United Kingdom at two sites of work - the 
laboratory and the clinic - examining the translational operation. They both work on HD, they 
collaborate directly, and some key personnel work in both. The first, conducted by [Author 
1], was a fifteen-month ethnography of Headlab; a cell laboratory conducting foetal tissue 
transplantation trials for HD. Twenty-five days of laboratory observation were conducted at 
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both the cell laboratory and its animal house. Handwritten field notes were taken during 
observation days and typed up in the evenings. In addition, fifteen semi-structured interviews 
were conducted with laboratory researchers. 
The second, conducted by [Author 2], was a 36-month ethnography of Neurotest; a 
disease management and research clinic for Huntington’s Disease.  [Author 2] followed a 
series of patients through their consultation with the director of Neurotest (Professor Craven), 
then on to any sessions with a psychiatrist, and into any research projects being carried out by 
psychologists, physiotherapists and research nurses. Ethnographic observations were made of 
waiting-room activity, clinical routines, neurological and cognitive testing, and patient 
consultations. These were in the form of observational field notes for each separate activity, 
including snippets of conversations, actions, expressions, and negotiations.  Clinic 
observations were conducted over twenty-nine days. Ten semi-structured interviews were 
conducted with patients and carers, seven semi-structured interviews with experts, and a 
further twenty-seven informal conversations with patients and carers. Thematic analysis of 
the observations and interviews from both sites was carried out during and after fieldwork. 
All names of the research sites and people mentioned in the article are pseudonyms. 
The ethnographies were analysed separately in the first instance. This paper derives 
from a subsequent exercise in synthesising findings and insights from a number of studies in 
this field (Lewis and Atkinson, 2011; Lewis et al., 2013; Stephens, Lewis and Atkinson, 
2013). Given this focus and given the different styles in which the authors wrote their field 
notes, our approach in this paper, following authors such as Rapp (2011), is not to present the 
field notes as separate freestanding pieces of data. But, rather to both describe and analyse the 
research sites in the body of the text (see Jackson, 1990 on field notes and head notes).  
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Such syntheses seek to transcend the site-specific nature of the originating 
ethnographies, in order to trace and follow the biomedical phenomena across a number of 
sites of knowledge-production. Headlab and Neurotest are part of a global collaborative 
approach to researching HD.  A collaborative approach to modern biomedicine is a trend that 
has been noted in earlier work when discussing stem cell science and its potential 
applications for diabetes (Wainwright et al. 2006).  Indeed, at our empirical settings we see 
the realization of two levels of collaboration.  In the first instance we are privy to a type of 
local translational collaboration.  This institutional alliance is a clear intention to strengthen 
interactions between Headlab and Neurotest.  The second involves collaboration on an 
international scale and the cooperation of multiple parties and agencies. We discuss both 
forms of collaboration as we follow the phenomena across various sites of work. 
Relocating Huntington’s Disease 
Translation between the clinic and the laboratory has involved the relocation of the disease 
from one specialty to another. Conceptually speaking, ‘the same’ medical condition can be 
located in a number of different specialties, each one framing the disease in a different way 
(Mol, 2002). Consequently diseases can follow a trajectory of migration between specialties, 
and of redefinition or reclassification. Such processes have been described by Latimer (2013), 
who traces the migration of dysmorphology, and Keating and Cambrosio (2003) who 
examine the field of hematology, across time and biomedical specialties. HD is rendered 
visible and researchable in the clinic we describe, and consequently in its paired laboratory, 
by a process of relocation from genetics to neurology. 
HD is an inherited disease of the brain (Harper, 1991). It is an incurable genetic 
condition in which symptoms typically develop between the ages of 35 and 50.  Symptoms 
include chronic choreic movements, which are jerky and uncontrollable, and a gradual loss of 
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insight and cognition that manifests as a dementia-type condition. Death occurs 
approximately 15 to 25 years after onset of symptoms (Roos et al., 1993). The cause has been 
identified as a dominantly inherited gene on chromosome 4, with an unstable protein 
sequence (The Huntington’s Disease Collaborative Research Group, 1993). The sequence 
(Cytosine, Adenine, Guanine) is known as a trinucleotide repeat. These CAG repetitions 
occur in everyone on chromosome 4, but in people who inherit the HD-type gene there are 
many more repetitions of CAG at this position. The disease pathology is the attaching of 
‘Huntingtin’ proteins to neurons in the brain in an irreversible process. The build-up of 
protein attachments causes loss of cells and function in particular areas of the brain. Currently 
there is no effective treatment for HD, which is physically, psychologically and socially 
debilitating.  
Despite the genetic component underpinning the disease, there has been a recent shift 
to understand the neurological basis of HD. The epistemological relocation of HD from 
genetics to neurology has been mirrored by the physical relocation and recasting of the clinic. 
The previous incarnation of Neurotest was a permanent base in the genetics department for 
management and palliative care. The general recollections of families prior to the current 
neurological research programme were that these were always routine clinic appointments, 
and that no treatment was available, but that they had a support network and a point of 
contact to make enquiries. In addition to the clinic there was also a home visit policy, which 
meant specialist genetic nurses and counsellors could meet the family outside the confines 
and formality of the clinic, and could examine the family and home situation.  This form of 
additional social support for discussion and advice was considered a valuable service for the 
families involved, enhanced by other forms of support such as social services. 
Whereas the previous clinic was permanently rooted, and centred on genetics, family 
members and local problems; today’s clinic is mobile and transferable with an emphasis on 
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data collection and redistribution on an international scale.  Today, Neurotest is a pop-up – 
documentation and personnel are easily transported in and out of its interim location for one 
day a week, and researchers travel from various parts of the university to perform clinical 
rituals and routines. Like most outpatient clinics, it is a meeting site for various clinical and 
scientific actors as well as patients. However, unlike most outpatient clinics, despite being 
based at a hospital, it is no regular National Health Service (NHS) setting. Although 
maintained to a hospital grade standard, the pop-up is situated in a research centre. This 
means that there is no permanent scrimmage for appointments and no constant churning over 
of patients. The clinic is, in contrast to most outpatients, quiet and spacious with a 
conspicuous lack of hospital trolleys and other NHS paraphernalia. At the end of day, the 
consultation room, the equipment and research paperwork are packed up and stored away 
until being laid out again in the next clinic. Contrast this picture of a portable, sterile (by this 
we do not just mean hygienic, but also barren) space that can pop-up anywhere at any time 
with the impressions of patients who consider the clinic to be a fixed abode existing all week 
around. For one day a week the perception of an anchored site provides a moment of repose 
in an otherwise shifting landscape where matter and matters – such as data, equipment and 
personnel - move from site to site being relocated in the process. To this end, today’s, 
Neurotest acts as a gateway to biomedical research as well as a place of clinical monitoring as 
the line between research and clinical management is muddied. The clinic is defined as a 
management clinic where patients can ask to be involved in research. This has meant that 
some patients have been referred to the clinic specifically because they know it is active in 
research. However, as part of its management role, patients partake in, among other things; 
psychological and cognitive testing where standardised data is collected (and then 
distributed).  
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The epistemological relocation of HD as a set of neurological signs and symptoms has 
therefore seen a transformation in the function of Neurotest, both for those working there and 
for the patients that attend the clinic. Viewed in this manner, interest in the disease is less 
about its genetic causation, and less about the personality of the patient or departure from 
normal life, and more about what happens in the patient’s brain. Drug developments that 
focus on brain functions, and the potential renewal of brain cells via technologies such as 
stem-cell or foetal tissue implantation, have relocated HD from the backwaters of genetic 
incurable disease, to the forefront of a new biotechnology based on research on brain-
function.  This has an effect on the general thoughts surrounding HD within families at risk 
or those affected – it is regarded less as a social and family problem and more as a biological 
condition. In turn, this facilitates understanding of the effects on different parts of the brain in 
different patients, allowing the individual patient to be better understood in terms of their 
specific difficulties.  Patients at Neurotest are inquisitive about developments in stem cells 
and are aware of the research at Headlab (Neurotest’s paired laboratory) and some of the 
clinical trials conducted by the laboratory’s collaborators in France. Relocation of the disease 
to the forefront of neuroscience therefore stimulates interest in scientific developments 
enabling laboratory products such as stem cells to travel – whether discursively or physically 
- between the laboratory and the clinic. Such bio-objects (Vermeulen, Tamminen and 
Webster, 2012) are the material reification of communication, functioning as boundary 
objects that connect different worlds (Star and Griesemer, 1989).  
Due to the paucity of any therapeutic alternatives for HD via medication, stem cells 
are capturing the imagination of Neurotest patients. That patients have heard of developments 
in stem cell research at Headlab, even though no trials were currently being conducted, 
consolidates a ‘community of promise’ (Martin, Brown and Kraft, 2008). This community 
helps foster relations between the laboratory where trials are expected to be conducted (Lewis 
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and Atkinson, 2011; Stephens, Lewis and Atkinson, 2013) and the clinic. Patients and 
families who attend today’s Neurotest therefore obtain tangible benefits in terms of time to 
discuss the disease, disease comprehension, and a sense of partnership with scientists and 
clinicians. Relocating the disorder from genetics into neuroscience has therefore also 
provided the opportunity for patients and patient groups to become a more active group in the 
biomedical process (Novas and Rose, 2000; van den Hoonard, 2009). 
The Collection, Standardisation and Distribution of Huntington’s Disease 
The relocation of the condition from genetics to neurology created the opportunity to 
intensively study the behavioural and cognitive trajectory of the condition in individuals and 
record the results. The course of increasing impairment could be traced and measured through 
standardised neurological assessments. This was, in turn, grounded in a global process of 
standardisation, through a major research collaboration. A global effort to address HD is 
pursued by mobilising the combined efforts of scientists and clinicians in an international 
project. The Huntington Project began in the USA, and encompasses most of Europe, parts of 
Asia, and extends into South America (Huntington’s Study Group, 2010).  This type of large-
scale multi-national collaboration involves the recruitment of large numbers of patients as 
participants in a longitudinal study on several heterogeneous projects and online research 
discussions. It also enrols different types of clinicians, biomedical scientists and health 
workers, working together  in different laboratories, clinics and countries. The data collected 
from these projects is brought together in an integrated approach, stored in databases, and 
made available for future HD researchers. Indeed, databases have become central instruments 
of scientific work and their development and maintenance is integral to the success of 
ongoing research (Hine, 2006; Millerand and Bowker, 2009).  In particular, the European 
Huntington Disease Network (EHDN) is taking part in Registry, a large multinational study 
that is ‘dedicated to finding treatments that make a difference for HD’ (EHDN, 2010). In 
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practice, this means that routine data collected and anonymised from HD patients at 
neurological clinics throughout the UK such as Neurotest is collated together with the same 
data from HD patients all over Europe, and then fed into a mass storage system to be 
retrieved by researchers all over the world. The collaborations and the practices of research 
are therefore both global and circular: the data collected is linked, accessible (both now and 
in the future), and all patients are contactable and re-contactable.  Such distributions form 
part of the circuits of translation. To borrow words from Keating and Cambrosio (2003) 
“unlike laboratory research, research at this level concerns less the production of local and 
unprecedented “epistemic things” than the constitution and circulation of protocols, 
instruments and substances between laboratories and the establishment of conventions that 
allow them to be used in the generation of biomedical facts” (p3). 
Clinical and cognitive HD tests carried out in participating clinics continue to be 
refined and standardised across the globe so that the resulting datasets can be shared and 
compared between laboratories. Data of this kind are heavily focussed on recording the 
actions of patients, linking the growing knowledge of brain-function to the observation of its 
embodied performance (Dumit, 2004; Rapp, 2011). This surveillance has resulted in a battery 
of testing procedures, through which HD patients are enrolled in the research process. As 
Petryna (2009) has demonstrated, the global dispersion of biomedical research places a 
premium on the reliability and standardisation of clinical trials. Local interventions must 
always be translated into global data.  This results in a further process of relocation – from 
patients to records and then on to shared-databases that form the basis of major research 
syntheses. Data such as this are mobile and can travel across various physical and virtual 
borders. In other words, the re-classification of HD as a neurological topic, for research 
purposes, is shaped by the demands for data that can be gathered and pooled on a trans-
national basis. 
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Standardisation results in documentary records that can migrate between one research 
centre and another, and measurements that can be pooled. Documents have a way of 
traversing boundaries and aligning practices, whilst the standards themselves are vehicles that 
help transport scientific fields from one domain to another (Eriksson and Webster, 2008). The 
expectation is that using a single, uniformed file, research groups around the globe can create 
an agreed ideal-type of HD making it easier to share research findings, obtain large samples 
of suitable patients and push the boundaries of the research faster without recourse to local 
protocols and ethical procedures. For example, the normal informed consent procedure would 
usually apply to just one particular study. However, the ongoing informed consent procedure 
for Registry allows patients to be re-contacted for other drug or treatment trials as and when 
they are available. This prevents lengthy delays in attempting to find a ‘suitable patient 
population’ since patients have already been identified. It also means researchers do not need 
to apply for new protocol approvals before contacting these patients. Indeed, this feature of 
recontactability is part of the ‘community of promise’, which has spiked the curiosity of the 
HD patients and families.  
All of this travelling – the transportation of standardised data, documents and 
procedures – can be performed whilst scientists, clinicians and, importantly, patients remain 
firmly rooted in their own locale.  Standards and regulation therefore play a fundamental role 
in stabilising a field, bringing momentary clarity to an often shifting landscape.  In this 
process, patients become calibrated, displaying key features of HD as manifested in the 
standardised research protocols and measurement instruments. As a consequence, it is not 
merely the biomedical science that is translated into patients: patients are themselves 
translated into ideal-typical displays of neurological impairment. 
Calibrating the Laboratory and Clinic 
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The processes of re-framing and re-locating are by no means one way. There is no single 
passage of ideas, materials or treatments from the laboratory to the clinic as the metaphor of 
bench to bedside would suggest. Rather, both the clinic and the laboratory need to be 
realigned. We have already discussed the way in which ‘the clinic’ is itself formulated as a 
site of research, and to that end the condition itself is re-framed in terms of neurological 
testing. Moreover, HD itself must be relocated back into the laboratory in order to render 
clinically observed signs and symptoms into researchable laboratory phenomena. In a process 
of relocation that parallels the clinical re-framing of HD, the disease is translated into a series 
of ‘doable’ phenomena (Fujimura, 1987). The neurological signs and symptoms are therefore 
reformulated into behavioural traits that can be observed and measured in laboratory models 
(mice and rats). 
 We have described the process of modelling in more detail elsewhere (Lewis et al. 
2013). Here we stress the significance of such modelling within the circuits of translation. 
There is a reflexive relationship between the laboratory and the clinic. The clinic frames the 
disease in ways that are susceptible to observation and measurement. The laboratory models 
the observable behaviours, and in turn provides a model of the disease that feeds directly back 
into clinical observations and interpretations. The disease entity (HD) is thus resolved into a 
number of different behaviours (such as gait or manifestations of memory) that can be 
induced and observed in laboratory animals. Knock-out mice or mice that have been given 
lesions can be induced to behave in a way that mirrors the observable behaviours of patients 
with HD; while laboratory rats, similarly treated, can be used to study more complex 
behavioural traits.  
If HD is to be studied in the laboratory, embodied in animal models, then there is a 
fundamental act of translation to be performed. HD has to be re-framed in terms of one or 
more animal models. The translation of the disease from human patients into laboratory 
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animals is, of course, one of the most significant of the multiple relocations and 
translocations that are required in order to make HD itself tractable. While it is conventional 
to discuss these issues in terms of animal ‘models’, this can readily gloss over the complex 
interpretative and judgmental processes whereby biomedical scientists have to decide 
collectively and locally what ‘counts’ as an adequate representation of HD in the laboratory 
animal. Consequently, the translation process calls for a series of equivalences to be 
established; both metaphoric and metonymic (see Lewis et al. 2013).   
 Laboratory models need to be established with sufficient fidelity to the human 
condition as to permit experimental interventions to assess the possible efficacy of cellular 
implants into human patients with HD.  Headlab had previous success with animal models 
that suggested transplanting cellular material into the brains of HD patients could have 
positive therapeutic effects. Based on the success of these experimental studies, the group 
planned to transplant embryonic striatal cell grafts collected from donated aborted foetuses 
into HD patients. The clinical trials were part of wider European research collaborations. 
Headlab hoped to assess the effectiveness of the trial by conducting transplant procedures 
with 10 patients and then assessing them for a further two years. The team had demonstrated 
some success with this approach in earlier years, but had been forced to suspend that work 
when regulatory directives required that laboratories be up-graded to clinical Good 
Manufacturing Practice standard (Lewis and Atkinson, 2011; Stephens, Lewis and Atkinson, 
2013). Having up-graded the laboratory facility, they were at the time of the fieldwork in a 
position to resume the work of translating laboratory experiments into preliminary trials on 
HD patients.  The relationship between Headlab and Neurotest is vital for the success of such 
a venture. The implantation of cells into human patients will once more relocate the 
experimental intervention from the laboratory to the clinic and from the model to the human 
patient. There is thus a dialectical relationship of modelling and calibration that shuttles back 
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and forth between laboratory modelling and clinical observation and measurement, which 
even extends to the type of care afforded to the animals and patients (see Friese, 2013). Just 
as the laboratory models the disease, so patients in turn are fashioned into models of 
neurological presentations.   This process of realignment renders congruent the laboratory 
model of HD in the neurological clinic and helps secure coherence for the classification of 
HD as neurological.  
As discussed, patients and carers of Neurotest had a very sketchy idea of the term 
‘research’, often describing their visit to the clinic as ‘just a check up’, or ‘a chat to see how 
things are progressing’.  The movement, psychological and cognitive tests were all perceived 
as ways to monitor the disease, and ways of calculating the health of the patient, rather than 
any specific investigative research exercise aimed at standardising cognitive tests and shaping 
HD categories. There is, and has been, an intimate dialectic between research and the clinic. 
Historically, this has been reflected in what has been described as the implicit ‘contract’ 
between the patient population and senior medical practitioners (Fox, 1959; Löwy 1996). The 
former receive treatment in the major teaching hospitals while the latter use them as ‘clinical 
material’ on which to base their clinical careers, experience and research. The original form 
of this relationship was based on the translation of treatment in one direction in return for 
greater knowledge of human ailments in the other: in return for medical care, clinicians 
gathered in-depth, local knowledge of the body. Here, we see a contemporary version of this 
intimate relationship, based in part on a renewed version of that tacit contract. In return for 
routine monitoring, clinicians and researchers at Neurotest are gathering in-depth, local 
knowledge of the body on a global scale. Similar to previous arrangements within medical 
history, there is a form of exchange within the translational process: this time it is the 
potential for clinical research and ‘check ups’ in exchange for standardised medical and 
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biomedical knowledge of the patient.1 The knowledge gleaned from HD patients is circulated 
back to the laboratory and forms part of the laboratory models of HD. Calibration between 
the laboratory and the clinic is therefore an institutional strategy implicated in the circuits of 
translation. We return to this is the next section. 
The Realignment of the Lab and the Clinic: the importance of boundary personnel 
Translation, in its various forms, implies border-crossings and the transcending of 
boundaries. Such boundaries can be soft or hard, visible or invisible, rigid or elastic. 
Boundaries, whether physical – as in the walls of a laboratory or clinic – or social and 
epistemological – as between disciplinary fields and territories - frame and legitimate the 
activities conducted within them. Translation is often accomplished in terms of the movement 
of objects, ideas and instruments across such terrains. Boundaries are crossed, bio-objects 
such as animal models (Vermeulen, Tamminen and Webster, 2012; Lewis et al., 2013), stem 
cells, standards and experiments travel (Petryna, 2009). But, the vectors for such movement 
and boundary-work also include personnel, who may move organizationally between the 
clinic and the laboratory.  
 As illustrated, the processes of translation are not based simply on local 
collaborations, or the physical proximity of laboratory and clinic, but such arrangements do 
facilitate the practical conduct of research and the everyday work of clinician-scientists. 
Headlab and Neurotest are based in the same city and some of the patients selected for 
Headlab’s foetal tissue transplant trial will likely be filtered from those who attend Neurotest. 
The positioning of a Clinical Professor (Professor Craven) who is able to navigate both sites 
is critical here. Building an infrastructure where the two institutions draw from one another 
                                                 
1  On a broader front, of course, this historical relationship finds its modern counterpart in the more explicit form 
of contract enshrined in the processes of informed consent and enrolment into clinical trials. 
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and where boundary people can work from varying points of the translational operation 
creates an environment that promotes smooth translational and reverse translational research. 
This multidisciplinary approach to treating a disease may determine the success of 
transplantation and therefore researchers from both sites require a broader perspective than 
that which they study.  The make-up of the Headlab group thus has a mixture of disciplinary 
hinterlands, comprised of a lattice of behavioural scientists, psychologists, cellular scientists 
and clinicians.  According to Rapp (2011) ‘under new interdisciplinary umbrellas, the 
migration of researchers and their shared topics, tools, grants, and regulatory ethos, becomes 
a practical possibility’ (p673).  Indeed, the Clinical Professor epitomises the notion of 
multiple identities and interdisciplinary research (see Calvert, 2012; Lewis and Bartlett, 2013 
on individual interdisciplinarity). Professor Craven combines clinical duties at Neurotest with 
her laboratory research at Headlab, including physical attendance at both sites. She identifies 
herself as both a clinician and a neurologist interested in neurodegeneration. Working as a 
clinician-scientist for 20 years, her interests extend to both developments in cell replacement 
therapy in the laboratory and the manifestations of HD in patients in the clinic. This has 
resulted in her travelling between her clinical duties at Neurotest and her laboratory research 
at Headlab. 
 According to Horig, Marincola and Marincola (2005) ‘dual-trained physician-
scientists are too few if for no other reason than the years required to fully train in both 
medicine and research’ (p707). They highlight the lack of such boundary people as a barrier 
to translational success. However, the clinician-scientist is a central actor in the translational 
work of contemporary biomedicine (Wilson-Kovacs and Hauskeller, 2012). Therefore 
Professor Craven is in a rather unusual but fundamental position as someone who has the 
skills to work comfortably at the bench and in the clinic. Over the years she has worked 
simultaneously with sets of ideas from both clinical practices with patients and from cellular 
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work in the scientific laboratory.  Llewellyn (2001) uses the metaphor of the two-way 
window to describe a similar relationship that clinical medical directors have with clinical 
practice on the one hand and management on the other. As the clinical neurologist Professor 
Craven has the knowledge to align work conducted in the laboratory with work done in the 
clinic. The close ties between the two settings further enable Professor Craven to push the 
translational agenda. 
 The intimate relationship between Headlab and Neurotest is fundamental to the 
success of translational research. As an example of how the laboratory is calibrated, basic 
research into animals measuring behavioural deficits of HD travels from Headlab to 
Neurotest, and findings showing that the cells they are looking at have a positive functional 
effect in good models are used to generate greater knowledge of the human disease. This is 
the traditional translational research model: the movement of basic research from the 
laboratory bench to the clinical bedside. Working together the two sites serve as discovery 
devices, pioneering medical practices by translating knowledge crafted in the laboratory into 
real-world practices in the clinic (Zerhouni, 2007). This is achieved on the back of a close 
working relationship between the two co-directors of the sites and the transfer of knowledge 
– through personnel, standards and objects - between the laboratory and the clinic.  
 However, the two groups also perform what is traditionally called reverse translation 
too. Headlab attempt to model the knowledge gleaned from the clinic on very early cognitive 
behavioural changes (often determined from clinical ‘management’ tests) into laboratory 
animals, before attempting to develop parallel tests on the animals back into patients. This 
illustrates how both the laboratory and the clinic require realignment as knowledge, materials 
and personnel flow in both directions between the two settings. In the same way that the 
disease is translated from the lab in to the human patient, so the disease is translated from the 
human patient to the laboratory (see Lewis et al., 2013).  The disease therefore goes through 
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a series of relocations and translocations.  Traditional boundaries between basic research and 
clinical research have softened as bridging devices such as animal models or ‘stem cells are 
used to transfer knowledge bi-directionally between the two sites. Behavioural animal 
experimentation is the essential basis for clinical cellular work, but knowledge collated in the 
clinic is also being built into the construction of animal models of the disease.  Therefore a 
feedback loop is created: the bench informs the clinic, the clinic informs the bench, and the 
bench will eventually inform the clinic once more. Here the circuits of translation between 
the two institutions are evident. 
 At the local level, it is clear that translational research is an inherently collaborative 
enterprise (Marincola, 2003). At our empirical settings, close institutional collaboration of 
this type is made possible because of some core operational alignments: similar instrumental 
interests, a common and co-dependent goal, boundary personnel and institutional proximity. 
Against this backdrop, it is the role of Professor Craven and Neurotest to link novel scientific 
advancements performed on rodents in the laboratory with the real-world experiences of 
living with the illness.  Accordingly, Neurotest can be seen to perform the role of bringing 
together scientific and technical knowledge with patient-disease led knowledge. In discussing 
‘translation’ it is all too easy to assume that ‘the clinic’ is merely the site at which biomedical 
innovations (produced at Headlab) are applied. Clearly this is not the case as the HD 
neurological clinic is itself a site where patients are enrolled as participants in trans-national 
research collaborations. Clinical observation and research-oriented data-collection are 
sometimes indistinguishable in the clinic. Indeed, it is in the clinic that research and clinical 
work are most closely intertwined, and where the boundaries are most obscured. 
Subsequently, some of the participating patients could not tell the difference between 
research and clinical management. This ambiguity has been illustrated previously by authors 
examining fields such as Cancer Genetics (Hallowell et al., 2009; Ponder et al., 2008). In a 
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similar vein, some patients in our study could not decipher whether they were part of a 
research project or not, particularly given that the research involved the collection of vast 
amounts of exploratory cognitive data that did not take the more typical form of a drug trial.  
 
 
Global Circuits and International Collaborations 
Clinical research, as well as basic research, often transcends national and cultural boundaries 
to become global partnerships and international collaborations. Headlab has working 
relationships with other laboratories in Europe, particularly in France. This collaborative 
approach is not unintentional. It is accepted within the HD community that transplantation 
projects can do some good and alleviate symptoms, although recent results have begun to 
appear from France and the USA which show limited and regressive results over time 
(Cichetti et al., 2009; Keene et al., 2009). With no alternative treatments, the moral mission 
of treating a debilitating disease has compelled laboratories to collaborate2.  
 Others have made us aware of the inherent problems and obstacles of translation 
(Wainwright et al., 2006). Boundaries are places of conflict. It is clear therefore that the 
various scientific laboratories, clinical groups and other interested parties must have a shared 
goal. Their interests need to be aligned from the beginning. This collaborative attitude has 
moved translational research from the lips of lab directors (a rhetorical device) to the benches 
of respected laboratories. For example, despite clinical trials having been halted at Headlab, 
clinical trials are within sight (and referred to in clinics by patients and clinicians). Moreover 
the trials continue to proceed in France. The corporeality of the procedure and the hope 
                                                 
2 Of course there may be additional economic and social rewards for collaborating as well as any moral 
responsibility. 
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invested in such a technique stimulates interest in the patient population. Joining forces to 
reach an agreed end goal of cellular transplantation, the triumvirate of laboratory, clinic and 
patient population also mobilises funding agencies and charities to support this type of 
research. Of course, this is not to suggest that there is not genuine competition between 
laboratories. Collaboration is a process of cooperation and competition (Atkinson, Batchelor 
and Parsons, 1998). However, we follow Fujimura (1987), in suggesting that the problem is 
doable when scientists can align tasks to three levels of organization – in this case, the 
laboratory, the clinic and the social world, which includes promissory futures. HD 
transplantation then becomes more than conceptual. It becomes tangible and viewed as 
dutiful across the globe.  
The processes of circulation between the laboratory, the clinic and patients/families 
draws attention to a more nuanced version of ‘translation’ than the mere transfer of 
knowledge and technique from one context to another. Such collaborations are only possible 
when there is a degree of international standardisation across and between groups that enable 
multiple parties to work together. As described, processes of alignment require data to be 
gathered, pooled and analysed in accordance with agreed protocols that extend across 
national boundaries, as well as bringing laboratory and clinical knowledge closer together. 
Central to the Huntington Project is the idea that using uniform files, research groups around 
the globe can construct one or more ideal-types of HD and rid the research field of its 
untidiness. Hacking (1983) argues laboratory work is not merely about representation, but 
also intervention: researchers are actively engaged in dexterously manipulating materials. 
The messiness of observational studies of HD that collect multiple sets of data finds its 
counterpart in the intervention of laboratory life. Standardising the types of data collected 
turns HD into a doable problem (see Fujimura, 1987; Stephens, Atkinson and Glasner, 2011).  
Standardisation of practical testing, and of recording results is an area of expansion at 
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Neurotest.  It was known that some clinicians carried out physical and cognitive testing in 
ways that had slight variation. In order to counter this (and to obtain ‘standardised data’), 
video training was given to formalise and create uniform tests.  In addition, specific forms 
and methods of registering clinical test results were developed, unified and used throughout 
all the research sites.  Standard documentation was produced for recording the results, which 
form part of the global database.  It is important to note that standardisation has not been 
carried out for the direct benefit of the patient. It has been developed to allow portable data to 
be easily recorded, manipulated and transferred between Neurotest, Headlab and their global 
partners. Data-types are identical enabling easier migration between sites and success is built-
in to their construction reflecting the actions and work of the researchers3.  
Clinic portals such as these databases provide common recording standards that 
enable meaningful local and national comparisons – that is, patients can be compared against 
one another and laboratories can collate findings.  Each site of clinic data collection has 
access to its own data immediately, whilst access to comparative sites may also be applied 
for. Comparison of this kind also extends informally to the ‘competition’ between sites’ 
successful levels of data collection. The Huntington Project and Registry are therefore 
examples of global standardisation (and regulation) that strive for global certainty by 
beginning to eradicate local practices, local interpretations and local contingency (see Leigh-
Star, 1985).  
Discussion 
The metaphors of translation and translational research have become prominent terms in 
describing biomedical research and its applications. While there have been long-standing 
                                                 
3 Of course, there may be aspects of interpretive flexibility (see Stephens, Atkinson and Glasner, 2011) in terms 
of the ways in which different sites understand the data. 
 23 
interactions between the laboratory and the clinic, the two have been recognised not merely 
as contrasting locales of biomedical practice, but also sites of contrasting modes of 
knowledge. This was the main message of Canguilhem’s (1978) pioneering work on the 
history and philosophy of medicine. Canguilhem suggests that ‘the clinic’ (as a mode of 
knowledge) is never explained solely from laboratory measurements and values. The 
pathological is never describable solely by extrapolating extreme differences from a norm or 
base. In that sense, ‘the clinic’ and its distinctive modes of perception is an autonomous 
realm. By the same token, the laboratory is also a relatively autonomous intellectual domain. 
The point of contrast is not to imply that these domains of knowledge-production and 
application are entirely independent, and that there is no possible epistemological interaction 
between them. Indeed Keating and Cambrosio have shown us how ‘biomedical platforms’ 
help bridge the gap between biology and clinical medicine (Cambrosio et al., 2009; Keating 
and Cambrosio, 2003). Rather, the paper demonstrates how biomedicalisation (Clarke et al., 
2010), biomedical platforms (Keating and Cambrosio, 2003) and bio-objects (Vermeulen, 
Tamminen and Webster, 2012) get produced. Translation is not a given – it needs to be made 
to happen. The synthesis between the laboratory and the clinic has to be achieved through a 
process of mutual adjustment. The paper documents precisely the ways in which biomedicine 
is made: translation does not just create new applications as Vannevar Bush proclaimed, it 
also sees new entities and new knowledges produced in the process.   
Fundamentally, translation implies movement between at least two different modes of 
perception, modes of interpretation and modes of practice, often referred to as the movement 
between bench to bedside and bedside to bench. These metaphorical obstacles all require 
some hurdling to cross what some writers, using another metaphor, have called the Valley of 
Death (Butler, 2008). In the paper we demonstrate some of the ways in which these obstacles 
are negotiated or brought into alignment within Huntington’s disease research. We put 
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forward that rather than a linear relationship between the clinic and the laboratory, there are 
multiple processes of relocation and translocation within the circuits of translation. In 
particular, HD has been relocated to neurology from genetics. This switch has been 
supplemented by promises of technical advances in the manipulation of tissue that mobilise 
communities of promise, the realignment and reconfiguration of the laboratory and the clinic, 
and the development of stable scientific infrastructures including the global standardisation of 
local practices and products. Indeed, regulation and standardisation play a central role in 
shaping and stabilising biomedical practices. Such processes can encourage, if not necessarily 
permit, the movement of ideas, artefacts and bio-objects between various local and 
international sites. 
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